Exherin (trifluoroacetate)
- Product Name
- Exherin (trifluoroacetate)
- CAS No.
- 1135237-88-5
- Chemical Name
- Exherin (trifluoroacetate)
- Synonyms
- ADH-1 trifluroacetate;ADH-1 TRIFLUOROACETATE;Exherin (trifluoroacetate);ADH-1 trifluoroacetate, 10 mM in DMSO;ADH 1,ADH1 trifluoroacetate,Inhibitor,ADH1,ADH-1,inhibit,ADH 1 trifluoroacetate
- CBNumber
- CB42735520
- Molecular Formula
- C24H35F3N8O8S2
- Formula Weight
- 684.7087096
- MOL File
- 1135237-88-5.mol
Exherin (trifluoroacetate) Property
- storage temp.
- Store at -20°C
- solubility
- DMSO:43.0(Max Conc. mg/mL);62.8(Max Conc. mM)
- form
- Solid
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- CD31004502
- Product name
- Exherintrifluoroacetate
- Purity
- 98+%
- Packaging
- 5mg
- Price
- $76
- Updated
- 2021/12/16
- Product number
- CD31004502
- Product name
- Exherintrifluoroacetate
- Purity
- 98+%
- Packaging
- 10mg
- Price
- $125
- Updated
- 2021/12/16
- Product number
- CD31004502
- Product name
- Exherintrifluoroacetate
- Purity
- 98+%
- Packaging
- 50mg
- Price
- $312
- Updated
- 2021/12/16
- Product number
- DC9532
- Product name
- Exherin(trifluoroacetate)
- Purity
- >98%
- Packaging
- 100mg
- Price
- $400
- Updated
- 2021/12/16
- Product number
- CD31004502
- Product name
- Exherintrifluoroacetate
- Purity
- 98+%
- Packaging
- 100mg
- Price
- $520
- Updated
- 2021/12/16
Exherin (trifluoroacetate) Chemical Properties,Usage,Production
Uses
ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.
in vivo
ADH-1 (50 mg/kg) significantly prevents tumor growth and metastasis in a mouse model for pancreatic cancer. ADH-1 prevents tumor cell invasion and metastasis in an orthotopic model for pancreatic cancer using N-cadherin overexpressing BxPC-3 cells[1]. ADH-1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model[2]. ADH-1 (10 mL/kg, i.p.) augmentation of melanoma tumor growth is overcome through its ability to make regionally infused melphalan more effective. ADH-1 mediated augmentation of melanoma tumor growth is not altered by regionally infused temozolomide. In A375, but not DM443 xenografts, ADH-1 treatment increases phosphorylation of AKT at serine 473. ADH-1 slightly diminishes N-cadherin expression in both xenografts[3].
References
[1] Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. DOI:10.1002/ijc.23027
[2] Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8. DOI:10.1097/CAD.0b013e328020043e
[3] Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77 DOI:10.1097/SLA.0000000000000635
Exherin (trifluoroacetate) Preparation Products And Raw materials
Raw materials
Preparation Products
Exherin (trifluoroacetate) Suppliers
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- +1-800-259-7612
- Fax
- +1-800-259-7612
- info@musechem.com
- Country
- United States
- ProdList
- 4660
- Advantage
- 60
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-631-485-4226
- Fax
- 1-631-614-7828
- inquiry@bocsci.com
- Country
- United States
- ProdList
- 19552
- Advantage
- 58
- Tel
- 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 9923
- Advantage
- 65
- Tel
- --
- Fax
- --
- sales@medchemexpress.com
- Country
- United States
- ProdList
- 6398
- Advantage
- 58